Clinical Trial Update: Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating early treatment with glatiramer acetate to delay conversion from clinically isolated syndrome to clinically definite multiple sclerosis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• COPAXONE (GLATIRAMER ACETATE)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2012-06-13